Genetics and adverse events with irinotecan treatment: what do we know?

被引：4

作者：

Paez, David ^{[1
,2
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain

[2] CIBERER, U705, Barcelona, Spain

来源：

PHARMACOGENOMICS | 2019年 / 20卷 / 06期

关键词：

INDUCED NEUTROPENIA; CHEMOTHERAPY; GENOTYPE; POLYMORPHISMS; COMBINATION; BEVACIZUMAB; THERAPY; CANCER;

D O I：

10.2217/pgs-2019-0012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：393 / 395

页数：3

共 20 条

[1] The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis [J].

Dias, M. M. ;

Pignon, J-P ;

Karapetis, C. S. ;

Boige, V. ;

Glimeliuss, B. ;

Kweekel, D. M. ;

Lara, P. N. ;

Laurent-Puig, P. ;

Martinez-Balibrea, E. ;

Paez, D. ;

Punt, C. J. A. ;

Redman, M. W. ;

Toffoli, G. ;

Wadelius, M. ;

McKinnon, R. A. ;

Sorich, M. J. .

PHARMACOGENOMICS JOURNAL, 2014, 14 (05) :424-431

[2] Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen):: A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer [J].

Ducreux, M ;

Ychou, M ;

Seitz, JF ;

Bonnay, M ;

Bexon, A ;

Armand, JP ;

Mahjoubi, M ;

Méry-Mignard, D ;

Rougier, P .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2901-2908

[3] Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer [J].

Fuchs, CS ;

Moore, MR ;

Harker, G ;

Villa, L ;

Rinaldi, D ;

Hecht, JR .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) :807-814

[4] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients [J].

Han, Fei-fei ;

Guo, Chang-long ;

Yu, Dan ;

Zhu, Jin ;

Gong, Li-li ;

Li, Guang-run ;

Lv, Ya-li ;

Liu, He ;

An, Guang-yu ;

Liu, Li-hong .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) :779-788

[5] A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy [J].

Henricks, Linda M. ;

Lunenburg, Carin A. T. C. ;

de Man, Femke M. ;

Meulendijks, Didier ;

Frederix, Geert W. J. ;

Kienhuis, Emma ;

Creemers, Geert-Jan ;

Baars, Arnold ;

Dezentje, Vincent O. ;

Imholz, Alexander L. T. ;

Jeurissen, Frank J. F. ;

Portielje, Johanna E. A. ;

Jansen, Rob L. H. ;

Hamberg, Paul ;

ten Tije, Albert J. ;

Droogendijk, Helga J. ;

Koopman, Miriam ;

Nieboer, Peter ;

van de Poel, Marlene H. W. ;

Mandigers, Caroline M. P. W. ;

Rosing, Hilde ;

Beijnen, Jos H. ;

van Werkhoven, Erik ;

van Kuilenburg, Andre B. P. ;

van Schaik, Ron H. N. ;

Mathijssen, Ron H. J. ;

Swen, Jesse J. ;

Gelderblom, Hans ;

Cats, Annemieke ;

Guchelaar, Henk-Jan ;

Schellens, Jan H. M. .

EUROPEAN JOURNAL OF CANCER, 2019, 107 :60-67

[6] DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis [J].

Henricks, Linda M. ;

Lunenburg, Carin A. T. C. ;

de Man, Femke M. ;

Meulendijks, Didier ;

Frederix, Geert W. J. ;

Kienhuis, Emma ;

Creemers, Geert-Jan ;

Baars, Arnold ;

Dezentje, Vincent O. ;

Imholz, Alexander L. T. ;

Jeurissen, Frank J. F. ;

Portielje, Johanna E. A. ;

Jansen, Rob L. H. ;

Hamberg, Paul ;

ten Tije, Albert J. ;

Droogendijk, Helga J. ;

Koopman, Miriam ;

Nieboer, Peter ;

van de Poel, Marlene H. W. ;

Mandigers, Caroline M. P. W. ;

Rosing, Hilde ;

Beijnen, Jos H. ;

van Werkhoven, Erik ;

van Kuilenburg, Andre B. P. ;

van Schaik, Ron H. N. ;

Mathijssen, Ron H. J. ;

Swen, Jesse J. ;

Gelderblom, Hans ;

Cats, Annemieke ;

Guchelaar, Henk-Jan ;

Schellens, Jan H. M. .

LANCET ONCOLOGY, 2018, 19 (11) :1459-1467

[7] UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters [J].

Hoskins, Janelle M. ;

Goldberg, Richard M. ;

Qu, Pingping ;

Ibrahim, Joseph G. ;

McLeod, Howard L. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (17) :1290-1295

[8] Irinogenetics and UGT1A:: From genotypes to haplotypes [J].

Innocenti, F ;

Ratain, MJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) :495-500

[9] Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan [J].

Innocenti, F ;

Undevia, SD ;

Iyer, L ;

Chen, PX ;

Das, S ;

Kocherginsky, M ;

Karrison, T ;

Janisch, L ;

Ramírez, J ;

Rudin, CM ;

Vokes, EE ;

Ratain, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1382-1388

[10] A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer [J].

Marcuello, E. ;

Paez, D. ;

Pare, L. ;

Salazar, J. ;

Sebio, A. ;

del Rio, E. ;

Baiget, M. .

BRITISH JOURNAL OF CANCER, 2011, 105 (01) :53-57

← 1 2 →